期刊文献+

血浆脂蛋白相关磷脂酶A2活性与冠脉病变程度和冠心病的关系分析 被引量:4

Analysis on the correlation of the activity of plasma lipoprotein associated phospholipids A2 with the severity of coronary artery lesions and coronary heart disease
下载PDF
导出
摘要 目的探讨临床中血浆脂蛋白相关磷脂酶A2(Lp~PLA2)活性与冠脉病变程度和冠心病的相关性。方法选取高州市人民医院心血管内科2012年1月~2013年6月60例冠心病患者为研究组,同期60例行冠状动脉造影术(CAG)未见有冠状动脉狭窄的患者为对照组,并将研究组中冠心病的临床类型和冠脉病变支数以及Gensini积分分为不同亚组。采取ELISA法测定Lp—PLA2水平。结果研究组中稳定型心绞痛、不稳定型心绞痛、心肌梗死患者的Lp—PLA2活性分别为(26.32±0.77)、(29.14±0.42)、(32.21±0.78)μmol/(min·mL),均明显高于对照组[(21.32±1.56)μmol/(min·mL)],差异有统计学意义(P〈0.05);且稳定型心绞痛、不稳定型心绞痛、心肌梗死患者的Lp—PLA2活性比较差异也有统计学意义(P〈0.05)。研究组中单支病变和双支病变以及三支病变的Lp—PLA2活性分别为(26.13±1.45)、(28.78±1.36)、(31.67±1.47)μmol/(min·mL),均明显高于对照组[(21.32±1.56)μmol/(min·mL)],差异有统计学意义(p〈0.05);且单支病变和双支病变以及三支病变患者的Lp—PLA2活性比较差异也有统计学意义(P〈0.05)。研究组中0~〈20分和20~〈40分以及≥40分的Lp—PLA2活性分别为(26.07±1.32)、(28.71±1.27)、(31.78±1.41)μmol/(min·mL),均明显高于对照组[(21.32±1.56)μmol/(min·mL)],差异有统计学意义(P〈0.05);且0~〈20分和20~〈40分以及≥40分患者的Lp—PLA2活性比较差异也有统计学意义(P〈0.05)。结论Lp—PLA2与冠心病的发生具有一定的联系,对该病的预测具有一定的意义。同时,该指标活性能够有效地反映出冠状动脉硬化的病变程度。 Objective To explore the correlation of the activity of plasma lipoprotein associated phospholipids A2 (Lp- PLA2) with the severity of coronary artery lesions and coronary heart disease in clinic. Methods 60 eases of patients with coronary heart disease in Department of Cardiovascular Medicine in the People's Hospital of Gaozhou from January 2012 to June 2013 were chosen as study group, in the same period, 60 cases of patients without coronary artery stenosis detected by CAG were as control group. The clinical types of coronary heart disease, the number of coronary artery lesions and Gensini scores in the study group were divided into different subgroups. The level of Lp-PLA2 was detected by ELISA method. Results The activities of Lp-PLA2 of stable angina, unstable angina, myocardial infarction in study group were (26.32±0.77), (29.14±0.42), (32.21±0.78) μmol/(min· mL), which were significantly higher than that in the control group [(21.32±1.56) μmol/(min·mL)], the differences were statistically significant (P 〈 0.05); and the Lp- PLA2 activities of stable angina, unstable angina, myocardial infarction also had significant differences (P 〈 0.05). The activities of Lp-PLA2 of single vessel lesion and double branch lesions and three lesions in the study group were (26.13±1.45), (28.78±1.36), (31.67±1.47) μmol/(min·mL), which were significantly higher than that in the control group [(21.32±1.56) μmol/(min·mL)], the differences were statistically significant (P 〈 0.05); and the Lp-PLA2 activities of the single branch lesion and double branch lesions and three lesions also had significant differences (P 〈 0.05). The activities of Lo-PLA2 of 0-〈20 scores, 20-〈40 scores and ≥40 scores in the study group were (26.07±1.32), (28.71±1.27), (31.78±1.41) μmol/(min·mL), which were significantly higher than that in the control group [(21.32±1.56) μmol/(min·mL)], the differences were statistically significant (P 〈 0.05), and the Lp-PLA2 activities of 0-〈20 scores, 20-〈40 scores and ≥40 scores also had statistically significant differences (P 〈 0.05). Conclusion Lp-PLA2 has a connection with the occurence of coronary heart disease, which has a certain significance for the prediction of the disease. At the same time, the activity of this index can effectively reflect the severity of coronary atherosclerosis.
出处 《中国医药导报》 CAS 2014年第16期45-47,共3页 China Medical Herald
基金 广东省茂名市医学类科技计划项目(编号2013 0330)
关键词 冠状动脉硬化 病变程度 冠心病 脂蛋白相关磷脂酶A2 Coronary arteriosclerosis Lesion Coronary heart disease Lipoprotein associated phospholipids A2
  • 相关文献

参考文献11

二级参考文献96

  • 1王学东,丛海霞,杜立杰,李家鏐,陈金玲.冠心病患者血尿酸水平及与心功能关系的研究[J].中国医药导刊,2004,6(3):162-163. 被引量:9
  • 2黄瑄,郑刚.颈动脉内膜中层厚度与动脉粥样硬化的关系及临床意义[J].华夏医学,2005,18(6):1063-1064. 被引量:8
  • 3刘甲兴,郑兴,秦永文,丁继军,赵仙先,曹江.脂蛋白相关性磷脂酶A_2活性能反映冠状动脉粥样硬化病变程度[J].第二军医大学学报,2006,27(4):391-395. 被引量:31
  • 4杨绍辉.高血压与血尿酸水平关系的临床观察[J].中国医药导刊,2006,8(4):247-248. 被引量:2
  • 5Oei HH,van der Meer IM,Hofman A,et al.Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke:the Rotterdam Study[J].Circulation,2005,8,111(5):570-575.
  • 6Ballantyne CM,Hoogeveen RC,Bang H,et al.Lipoprotein-associated phospholipase A2,highsensitivity C-reactive p rotein,and risk for incident coronary heart disease in middle aged men and women in the Atherosclerosis Risk in Communities(ARIC)study[J].Circulation,2004,109(7):837-842.
  • 7Kolodgie FD,Burke AP,Skorija KS,et al.Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis[J].Arterioscler Thromb Vasc Biol,2006,26(11):2523-2529.
  • 8Blankenberg S,Stengel D,Rupprecht HJ,et al.Plasma PAF-acetylhydrolase in patientswith coronary artery disease:results of a crosssectional analysis[J].J Lipid Res,2003,44:1381-1386.
  • 9Six DA, Dennis EA. The expanding superfamily of phospholipase A ( 2 ) enzymes: classification and characterization. Biochim Biophys Acta,2000,1488 : 1-19.
  • 10Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein ( a ) -associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol,2007,27:2094-2099.

共引文献39

同被引文献36

  • 1Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecast- ing the future of cardiovascular disease in the United States a policy statement from the American heart associa- tion[J]. Circulation, 2011, 123(8):933-944.
  • 2Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evi- dence from a comprehensive network meta-analysis [J]. Lancet, 2012, 379(9824):1393-1402.
  • 3Epps KC, Wilensky RL. Lp-PLA2-a novel risk factor for high-risk coronary and carotid artery disease[J]. J Intern Med, 2011, 269(1):94-106.
  • 4陈灏珠.内科学[M].8版.北京:人民卫生出版社,2002:47.
  • 5Macphee CH, Moores KE, Boyd I-IF, et al. Lipoprotein-as- sociated phospholipase A2, platelet-activating factor acety|- hydrolase, generates two bioactive products during the oxi-dation of low-density lipoprotein: use of a novel inhibitor[J]. Biochem J, 1999, 338(Pt 2):479-487.
  • 6Ikonomidis I, Michalakeas CA, Lekakis J, et al. The role of lipoprotein-associated phospholipase A2(Lp-PLA2) in car- diovascular disease[J]. Rev Recent Clin Trials, 2011, 6(2): 108-113.
  • 7Hakkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein- associated phospholipase A(2), platelet-activating factor ace tylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions[J]. Arterioscler Thromb Vase Biol, 1999, 19(12):2909-2917.
  • 8Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis [J]. Arterioscler Thromb Vasc Biol, 2006, 26(11):2523-2529.
  • 9Ikonomidis I, Kadoglou NN, Tritakis V, et al. Association of Lp-PLA2 with digital reactive hyperemia, coronary flow re serve, carotid atherosclerosis and arterial stiffness in coronary artery disease[J]. Atherosclerosis, 2014 , 234 ( 1 ) : 34-41.
  • 10Jabor B1, Choi H, Ruel I, etai. Lipoprotein-associated phospho lipase A (2) ( Lp-PLA (2)) in acute coronary syndrome: rela- tionship with low-density lipoprotein cholesterol[J]. Can J Car- diol,2013,29(12) :1679 -1686.

引证文献4

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部